Maintenance Notice (3:30 - 8:30 AM June 28, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Life Science News June 2025 | [TCIPracticalExample] Goldberg Amination Using... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 302962-49-8 | 产品编码: D5949
Dasatinib
×
![]()
×
| 产品编码 | D5949 |
| 纯度/分析方法 | >95.0%(T)(HPLC) |
| 分子式/分子量 | C__2__2H__2__6ClN__7O__2S = 488.01 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷冻 (<0°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 302962-49-8 |
| Reaxys-RN | 9966762 |
| PubChem物质ID | 468591660 |
| MDL编号 | MFCD11046566 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Purity(Nonaqueous Titration) | min. 95.0 % |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 280 °C |
GHS
| 象形图 |
|
| 信号词 | Danger |
| 危险性说明 | H301 : Toxic if swallowed. H361 : Suspected of damaging fertility or the unborn child. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相关法规
| RTECS# | XJ3466000 |
运输信息
| UN编号 | UN2811 |
| 类别 | 6.1 |
| 包装类别 | III |
| HS编码* | 2934.10-000 |
应用
Dasatinib: A Multitargeted Inhibitor of Tyrosine Kinases
Dasatinib (BMS-354825) is an oral, multitargeted inhibitor of tyrosine kinases, including BCR-ABL fusion protein, SRC family kinases (SRC, LCK, YES, FYN), c-KIT, erythropoietin-producing hepatocellular receptor A2 (EPHA2), and platelet-derived growth factor receptor β (PDGFRβ). In vitro studies have shown that dasatinib is active in leukemic cell lines representing variants of imatinib mesylate [I0936] sensitive and resistant disease. Dasatinib inhibits the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. (The product is for research purpose only.)
References
- Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent AntitumorActivity in Preclinical Assays
- Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
- Dasatinib: an anti-tumor agent via Src inhibition (a review)
- Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。